Meridian Bioscience Inc. (NASDAQ:VIVO) previous close was $19.10 while the outstanding shares total 43.10M. The firm has a beta of 0.48, a 12-month trailing P/E ratio of 11.85, and a growth ratio of 0.70. VIVO’s shares traded higher over the last trading session, gaining 0.16% on 06/03/21. The shares fell to a low of $18.77 before closing at $19.13. Intraday shares traded counted 0.65 million, which was 9.72% higher than its 30-day average trading volume of 723.20K. The stock’s Relative Strength Index (RSI) is 40.17, with weekly volatility at 5.79% and ATR at 1.03. The VIVO stock’s 52-week price range has touched low of $12.98 and a $30.65 high.
Investors have identified the Diagnostics & Research company Meridian Bioscience Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $837.32 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Meridian Bioscience Inc. (VIVO) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 188.29 million total, with 50.31 million as their total liabilities.
VIVO were able to record 29.54 million as free cash flow during the 07/29/2021 quarter of the year, this saw their quarterly net cash flow reduce by 9.86 million. In cash movements, the company had a total of 41.49 million as operating cash flow.
Potential earnings growth for Meridian Bioscience Inc. (VIVO)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/29/2021 quarter of the year, Meridian Bioscience Inc. recorded a total of 85.26 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 32.8% coming in sequential stages and their sales for the 07/29/2021 quarter reducing by -8.98%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 27.49 million trying to sell their products during the last quarter, with the result yielding a gross income of 57.77 million. This allows shareholders to hold on to 43.10M with the recently reported earning now reading 0.61 cents per share. This is a figure that compared to analyst’s prediction for their 07/29/2021 (0.56 cents a share).
Having a look at the company’s valuation, the company is expected to record 1.16 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on VIVO sounds very interesting.
Is the stock of VIVO attractive?
In related news, Chief Executive Officer, Kenny John P. sold 30,000 shares of the company’s stock in a transaction that recorded on Mar 17. The sale was performed at an average price of 25.00, for a total value of 750,000. As the sale deal closes, the Chief Executive Officer, Kenny John P. now sold 10,000 shares of the company’s stock, valued at 250,000. Also, Chief Executive Officer, Kenny John P. sold 2,359 shares of the company’s stock in a deal that was recorded on Feb 16. The shares were price at an average price of 30.35 per share, with a total market value of 71,604. Following this completion of acquisition, the Chief Executive Officer, Kenny John P. now holds 26,181 shares of the company’s stock, valued at 789,085. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.
4 out of 4 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Meridian Bioscience Inc.. 0 analysts has assigned a Sell rating on the VIVO stock. The 12-month mean consensus price target for the company’s shares has been set at $32.00.